GENMAB A/S
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
METHOD OF TREATING CANCER BY ADMINISTERING AN ANTIBODY WHICH BINDS TO 5T4
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?
On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator’s choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. The clarification confirmed that in the United […]
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Media Release COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; July 23, 2026 Genmab and AbbVie clarify overall survival (OS) was the sole U.S. primary endpoint in the Phase 3 EPCORE® DLBCL-1 trial and was not met Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today provided clarification on the primary endpoints from the Phase 3 EPCORE® DLBCL-1 study evaluating monotherapy epcoritamab (DuoBody®-CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, compared with investigato
Congressional Trades in $GMAB
Insider Trades (Form 4)
No Form 4 insider trades found for $GMAB.
Key People
No individuals linked to this entity yet.
Political Giving
No disclosed PAC contributions found for this entity.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro